Histone deacetylase (HDAC) inhibitors
- Name
- Histone deacetylase (HDAC) inhibitors
- Accession Number
- DBCAT005738
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Vorinostat A histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies. Belinostat A histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Romidepsin A histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma. Panobinostat A non-selective histone deacetylase inhibitor used to treat multiple myeloma in combination with other antineoplastic agents. Entinostat Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic... - Drugs & Drug Targets